Derm Fall Clinical

This post-hoc analysis highlights nemolizumab’s long-term efficacy and safety in adolescents with moderate-to-severe atopic dermatitis.

The Psoriasis Study of Health Outcomes (PSoHO) was designed as a 36-month, non-interventional, international cohort study of patients with psoriasis.

In this analysis, investigators examined the efficacy of baricitinib in terms of its impact on disease activity and progression of frontal fibrosing alopecia.

These data highlight a super-response following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe CHE.

The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.

At the Fall Clinical Dermatology Conference, this session provided clinical pearls to clinicians in the pediatric dermatology space.

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Kwatra spoke at Fall Clinical about several key highlights from his sessions discussing atopic dermatitis, prurigo nodularis, and the OX40 ligand (OX40L).

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.

In this segment of his Fall Clinical interview, Nestor discussed actinic keratosis and shifts in the rates of skin cancer.

Nestor spoke in this interview about avoiding cosmetic complications and educating patients on available treatments like toxins and fillers.

In the CHECK study, a cross-sectional survey of over 10,000 participants, the prevalence of chronic hand eczema (CHE) in the US was highlighted.

This Fall Clinical interview features a series of highlights from Culton’s portion of the session ‘Bullous Pemphigoid: The Time to Treat is Now.’

In this interview at Fall Clinical, Song highlights takeaways from his portion of the session ‘30 Tips in 30 Minutes.’

Song interviewed with the team regarding his session, discussing recent data on IL-23 inhibition in patients with psoriasis.

Alexis spoke in this segment of his Fall Clinical interview on takeaways from his presentation titled ‘Melasma and Other Hyperpigmentation Disorders.’

In this Fall Clinical interview, Alexis highlights several tips for clinicians covered in his session at the conference titled ‘30 Tips in 30 Minutes.’

This interview with Prince Adotama, MD, at Fall Clinical highlights several takeaways from his session on treating bullous pemphigoid.

In this segment of her Fall Clinical interview, Shahriari highlights a session IL-13 inhibition and management of atopic dermatitis.

This interview at Fall Clinical highlights a session on clinical pearls related to diagnosing prurigo nodularis in patients with skin of color.

Pooled results from two Phase 3 trials show DFD-29 achieved a 62.7% IGA success rate and significantly greater lesion reduction than both doxycycline and placebo.

These recent findings on roflumilast cream (Zoryve) highlight the topical agent’s efficacy and impacts on quality of life in younger patients with atopic dermatitis.

At Week 52, icotrokinra achieved clear/almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis, with consistent safety and durable responses.

Once-daily oral baricitinib was shown to result in meaningful hair regrowth after 1 year in adolescent patients with alopecia areata.

Lilly's lebrikizumab-lbkz treatment, used once every 8 weeks, resulted in durable disease control in moderate-to-severe atopic dermatitis.

This interview highlights the takeaways from Nestor’s Fall Clinical session titled ‘What Did 2025 Bring to the Table in Dermatology?’

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.